Patrick O’Brien is co-head of the firm’s securities and public companies practice. He concentrates his practice on representing companies and underwriters in financings as well as public and private companies in M&A transactions.
Patrick has extensive experience representing healthcare, life sciences and technology companies and underwriters in connection with equity and debt offerings, as well as mergers and acquisitions and royalty monetizations.
JD, Boston University School of Law, 1989
BA, University of Illinois, 1983
New York, 2012
Represented the following issuers in their proposed initial public offerings: Zai Labs, IMS Health Holdings, Inc., Aptalis Holdings Inc., Par Pharmaceutical Holdings, Inc., Iasis Healthcare Corporation, and Petco Holdings, Inc.
Represented Alexion Pharmaceuticals, Inc. in its $610 million acquisition (plus milestones) of Enobia Inc.
Represented LA BioMED and UCLA in its sale of a portion of its royalty interest in Kybella.
Represented Canadian Pension Plan Investment Boardin the purchase of a $168 million royalty interest from Dana Farber Cancer Institute.
Represented a publicly traded specialty pharmaceutical company in a complex acquisition and related royalty based financing.
Represented a university in connection with the sale of a pharmaceutical royalty stream.